Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:166-172
Published online before print November 1, 2007, doi: 10.1161/ATVBAHA.107.153262
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/1/166    most recent
ATVBAHA.107.153262v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perlstein, T. S.
Right arrow Articles by Creager, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perlstein, T. S.
Right arrow Articles by Creager, M. A.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:166.)
© 2008 American Heart Association, Inc.


Clinical and Population Studies

Serum Total Bilirubin Level and Prevalent Lower-Extremity Peripheral Arterial Disease

National Health and Nutrition Examination Survey (NHANES) 1999 to 2004

Todd S. Perlstein; Reena L. Pande; Joshua A. Beckman; Mark A. Creager

From the Department of Medicine, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Todd S. Perlstein, MD, MMSc, Brigham and Women’s Hospital, Cardiovascular Division, 75 Francis Street, A Bldg, 3rd floor, Boston, MA 02115. E-mail tperlstein{at}partners.org

Abstract

Background— Bilirubin, with recently recognized antioxidant and antiinflammatory activity, has emerged as a candidate for atheroprotection. We hypothesized that higher levels of bilirubin would reduce susceptibility to peripheral arterial disease (PAD).

Methods and Results— We analyzed 7075 adults with data available on the ankle brachial index, serum total bilirubin level, and PAD risk factors in the National Health and Nutrition Examination Survey (1999 to 2004), a nationally representative cross-sectional examination of the United States population. A 0.1 mg/dL increase in bilirubin level was associated with a 6% reduction in the odds of PAD (OR 0.94 [95% CI 0.90 to 0.98]) after adjustment for age, gender, race/ethnicity, smoking status, diabetes, hypertension, hypercholesterolemia, chronic kidney disease, CRP, and homocysteine. This result was not dependent on bilirubin levels above the reference range, liver disease, or alcohol intake. The inverse association of bilirubin with PAD tended to be stronger among men (OR 0.90 [95% CI 0.85 to 0.96]) compared with women (OR 0.97 [95% CI 0.91 to 1.04]; Pinteraction=0.05), and was stronger among active smokers (OR 0.81 [95% CI 0.73 to 0.90]) compared with nonsmokers (OR 0.97 [95% CI 0.93 to 1.02]; Pinteraction<0.01).

Conclusions— Increased serum total bilirubin level is associated with reduced PAD prevalence. This result is consistent with the hypothesis that bilirubin is protective from PAD.

Bilirubin has antiinflammatory, antioxidant, and possibly atheroprotective properties. Among 7075 adults in the NHANES 1999 to 2004, we found that bilirubin was inversely associated with PAD prevalence independent of traditional and novel PAD risk factors. Higher bilirubin levels may therefore be associated with lessened susceptibility to PAD.


Key Words: bilirubin • peripheral vascular disease • PVD • epidemiology • Centers for Disease Control and Prevention • CDC • National Health and Nutrition Examination Survey • NHANES




This article has been cited by other articles:


Home page
StrokeHome page
H. Kimm, J. E. Yun, J. Jo, and S. H. Jee
Low Serum Bilirubin Level as an Independent Predictor of Stroke Incidence: A Prospective Study in Korean Men and Women
Stroke, November 1, 2009; 40(11): 3422 - 3427.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Maestro, M. Terdoslavich, A. Vanzo, A. Kuku, F. Tramer, V. Nicolin, F. Micali, G. Decorti, and S. Passamonti
Expression of bilitranslocase in the vascular endothelium and its function as a flavonoid transporter
Cardiovasc Res, September 15, 2009; (2009) cvp290v2.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
S. Y. Yeh, J. Doupis, S. Rahangdale, S. Horr, A. Malhotra, and A. Veves
Total serum bilirubin does not affect vascular reactivity in patients with diabetes
Vascular Medicine, May 1, 2009; 14(2): 129 - 136.
[Abstract] [PDF]


Home page
JWatch Oncology and HematologyHome page
Bilirubin Protects Against Peripheral Arterial Disease
Journal Watch Oncology and Hematology, March 11, 2008; 2008(311): 2 - 2.
[Full Text]